COVID-19
Conditions
Keywords
COVID-19 vaccine, Booster
Brief summary
Open-label, prospective intervention study of IndoVac® as a single, homologous booster dose
Detailed description
This trial is open-label, prospective intervention study. A total of 150 subjects who had previously received complete primary doses of IndoVac® in phase III and are willing to participate in the study by signing the consent form, will be involved in this trial. The regimen of the vaccine 0.5 ml injected as a single booster dose. Evaluation will be conducted for safety and immunogenicity for all subjects. Safety evaluation include AEs until 28 days post booster dose, with AESIs and SAEs throughout the trial. Immunogenicity evaluation will compare pre-booster antibody titer (baseline) to post- booster antibody titer at 14 days, 28 days, 3 months, 6 months, and 12 months timepoint. Interim evaluation will be performed at 14 days post booster dose for Emergency Use Authorization (EUA) consideration. All subjects will be followed up until 12 months post booster dose.
Interventions
BIOLOGICALSARS-CoV-2 Subunit Recombinant Protein Vaccine
SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT Bio Farma
Sponsors
PT Bio Farma
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Clinically healthy subjects aged 18 years and above. 2. Subjects had previously received complete primary doses of IndoVac® with the last dose administered minimum 12 months but no longer than 18 months prior to inclusion. 3. Subjects have been informed properly regarding the study and signed the informed consent form. 4. Subjects will commit to comply with the instructions of the investigator and the schedule of the trial.
Exclusion criteria
1. Subjects concomitantly enrolled or scheduled to be enrolled in another trial. 2. Subjects had received booster dose of COVID-19 vaccine. 3. History of COVID-19 within 3 months prior to enrollment (based on anamnesis or other examinations). 4. Evolving mild, moderate, or severe illness, especially infectious disease, or fever (body temperature ≥37.5°C, measured with infrared thermometer/thermal gun). 5. Women who are pregnant or planning to become pregnant during the study period (judged by self- report of subjects and urine pregnancy test results). 6. History of uncontrolled asthma, allergy to vaccines or vaccine ingredients, and severe adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema. 7. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection. 8. Patients with serious chronic diseases (serious cardiovascular diseases, uncontrolled hypertension or diabetes, liver or kidney diseases, malignant tumors, etc.) which according to the investigator might interfere with the assessment of the trial objectives. 9. History of confirmed or suspected immunosuppressive or immunodeficient state or in the previous 4 weeks had received a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, or long- term corticosteroid therapy (\> 2 weeks)). 10. History of uncontrolled epilepsy or other progressive neurological disorders, such as Guillain- Barre Syndrome. 11. Subjects had received any vaccination (other than COVID-19 vaccine) within 1 month before IP immunization. 12. Subjects plan to move from the study area before the end of study period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Neutralizing antibody before and at 14 days after booster dose | Baseline, 14 days after booster dose | Geometric Mean Titer (GMT) and Geometric Mean Fold Ratio (GMFR) of SARS-CoV-2 neutralizing antibody against Omicron variant |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neutralizing antibody at 28 days after booster dose | Baseline, 14 days, 28 days after booster dose | Geometric Mean Titer (GMT) and Geometric Mean Fold Ratio (GMFR) of SARS-CoV-2 neutralizing antibody against Omicron variant |
| RBD-binding IgG antibody before, at 14 days and 28 days after booster dose | Baseline, 14 days, 28 days after booster dose | Geometric Mean Titer (GMT) and Geometric Mean Fold Ratio (GMFR) of SARS-CoV-2 RBD-binding IgG antibody |
| Antibody persistence at 3, 6, and 12 months after booster dose | Baseline, 3 months, 6 months, 12 months after booster dose | Geometric Mean Titer (GMT) and Geometric Mean Fold Ratio (GMFR) of SARS-CoV-2 RBD-binding IgG antibody |
| Safety after booster dose | Baseline to 12 months after booster dose | Number and percentage of subjects with solicited and unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs) |
Countries
Indonesia
Outcome results
None listed